Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H9N2O3S.Na |
| Molecular Weight | 236.223 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1
InChI
InChIKey=PQMSFAORUFMASU-UHFFFAOYSA-M
InChI=1S/C8H10N2O3S.Na/c1-6(11)10-14(12,13)8-4-2-7(9)3-5-8;/h2-5H,9H2,1H3,(H,10,11);/q;+1/p-1
| Molecular Formula | C8H10N2O3S |
| Molecular Weight | 214.242 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Sulfacetamide is a synthetic sulfonamide antibiotic, which exerts its effect through inhibition of bacterial dihydrofolate synthetase, an enzyme responsible for the conversion of p-aminobenzoic acid into folic acid in bacterias. The topical formulation of the drug is prescribed for the treatment of acne vulgaris and the ophtalmic formulation is used in patients with eye infections.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2364668 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | BLEPHAMIDE Approved UseBlephamide ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. Launch Date1961 |
|||
| Curative | KLARON Approved UseKlaron Lotion is indicated in the topical treatment of acne vulgaris. Launch Date1996 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Acute infectious conjunctivitis in childhood. | 2001 Jul |
|
| Topical bactrim versus trimethoprim and sulfonamide against nocardia keratitis. | 2001 Mar |
|
| Ocular nocardia infections with special emphasis on the cornea. | 2001 Mar-Apr |
|
| A status report on the medical management of rosacea: focus on topical therapies. | 2002 Nov |
|
| 3-Aminophenol as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives. | 2003 Dec |
|
| Rosacea. An overview of diagnosis and management. | 2004 Dec |
|
| The treatment of rosacea. | 2004 Jan |
|
| Rosac Cream With Sunscreens (sodium sulfacetamide 10% and sulfur 5%). | 2004 Mar-Apr |
|
| Rosacea: where are we now? | 2004 May-Jun |
|
| Nocardia keratitis in a human immunodeficiency virus patient. | 2004 May-Jun |
|
| Molecular characterization of bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase from Plasmodium falciparum. | 2004 Sep |
|
| Monitoring of five sulfonamide antibacterial residues in milk by in-tube solid-phase microextraction coupled to high-performance liquid chromatography. | 2005 Nov 2 |
|
| Researches concerning the synthesis and antituberculosis action of some new sulphacetamide derivatives. | 2006 Apr-Jun |
|
| Combination topical therapy in the treatment of acne. | 2006 Aug |
|
| Topical therapies for rosacea. | 2006 Jan |
|
| Simultaneous determination of 17 sulfonamides and the potentiators ormetoprim and trimethoprim in salmon muscle by liquid chromatography with tandem mass spectrometry detection. | 2007 Jan-Feb |
|
| Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. | 2007 Mar |
|
| Rosacea and its topical management. | 2009 Feb |
|
| Treatment of papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam. | 2009 Mar |
|
| A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. | 2009 Oct 23 |
|
| Updates on the pathophysiology and management of acne rosacea. | 2009 Sep |
|
| Interaction of topical sulfacetamide and topical dapsone with benzoyl peroxide. | 2009 Sep |
|
| Sulfacetamide loaded Eudragit® RL100 nanosuspension with potential for ocular delivery. | 2010 |
Patents
Sample Use Guides
Topical: apply a thin film to affected areas twice daily. Ophtalmic suspension/ointment: two drops of suspension should be instilled into the conjunctival sac every four hours during the day and at bedtime. A small amount, approximately 1/2 inch ribbon of ointment, should be applied in the conjunctival sac three or four times daily and once or twice at night.
Route of Administration:
Other
P. aeruginosa, S. marcescens, St. epidermidis, C.
albicans, and A. fumigatus (spores) were exposed to two ophthalmic solutions each formulated with 10% sodium sulfacetamide and a preservative. Sulfacetamide solutions preserved with thimerosal have MIC values ranging from 0.2 to 2.8 for the five test microorganisms. The solutions preserved with parabens exhibit slightly higher MIC values for Pseudomonas, Serratia, and spores of Aspergillus (1.5-6.5) and significantly higher MIC values for Staphylococcus and Candida (19.6 and 5.0, respectively).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:58:55 GMT 2023
by
admin
on
Sat Dec 16 03:58:55 GMT 2023
|
| Record UNII |
30760ZE777
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB20814
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
9327
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
4022878
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
204-848-4
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
127-56-0
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
63858
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
DTXSID40889336
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | |||
|
m10301
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY | Merck Index | ||
|
30760ZE777
Created by
admin on Sat Dec 16 03:58:55 GMT 2023 , Edited by admin on Sat Dec 16 03:58:55 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |